Prostate Cancer Clinical Trial
Official title:
A Randomized Trial of Short Versus Long Acting LHRH Agonist Preparation Prior to Transperineal Implantation of the Prostate
Brachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of
treatment for localized cancer of the prostate. TPIP has been used at the British Columbia
Cancer Agency (BCCA) since 1998. As part of the treatment, some patients also require
hormone therapy for 6 months. This is given as injections of a drug called an LHRH agonist.
The LHRH agonist is made either as short-acting (1-month) or long-acting (3 month)
injections. The LHRH agonist lowers testosterone levels, which helps make delivery of TPIP
easier, and more effective.
There are specific guidelines regarding the use of LHRH agonist treatment with
brachytherapy, however there is no policy whether short-acting or long-acting LHRH agonists
should be used.
Analysis of results from BC has shown that there seems to be a delay in the time in which
testosterone levels return to normal in men who receive the long-acting LHRH agonist
compared with the short-acting LHRH agonist, however this is not known for sure.
The suppression of testosterone to castrate levels has a definite advantage in terms of
prostate volume downsizing, disease control and ease of Brachytherapy, in this patient
population. The improved potency preservation rate seen with brachytherapy, when compared to
other treatments such as radical prostatectomy or external beam, may be an important
determinant in the patient's choice of treatment modality. Hence, testosterone recovery
should be an important endpoint to consider in this patient population since prolongation of
testosterone suppression may also delay the return of erectile function.
In order to compare the impact of LHRH agonist preparations on the rate of testosterone
recovery, we propose a randomized clinical trial using one versus three-month Leuprolide
preparations in patients otherwise suitable for our Brachytherapy Program.
The primary objective of this study is the median time to testosterone recovery in patients
receiving 6 X 1-month or 2 X 3-month LHrH preparations and TPIP as radical treatment for
limited stage prostate cancer.
In this context, testosterone recovery is defined as the return to the lower limit of normal
for the patient's age group as well as return to pre treatment levels.
Analysis will mainly focus on time to testosterone recovery as defined by return to the
lower limit of normal for the patient's age group as well as return to pre treatment levels.
The lower limits of normal are defined as 5.8nmol/L and 5.5nmol/L for < 50 and > 50 years
old
Changes in PSA level, QOL and erectile function will also be recorded
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |